Competitive and Technical Intelligence ToolBox

Nanoparticle delivery systems are a dynamic field that is changing the way active agents (e.g., therapeutic, diagnostic, and imaging agents) are developed and delivered. These small delivery vehicles are designed with the goal of (1) overcoming limitations such as short plasma half-life, stability issues, and potential immunogenicity associated with small molecule and biomacromolecular therapeutics, and (2) minimizing toxic side effects while maximizing therapeutic activity.1 Active agents that were once considered obsolete or unusable are finding new life when delivered in conjunction with a nanoparticle carrier. Nanoparticle carriers having varied structures and compositions are finding utility as treatments and diagnostics for diseases such as cancer, diabetes, and HIV/AIDS. The first nanoparticle-based therapeutics has already come to market and more will surely follow in this developing field. Source

Salix Pharmaceuticals , Ltd has announced that Salix Pharmaceuticals, Inc has filed a lawsuit in the US District Court of New Jersey against Novel Laboratories for infringement of the patent protecting Osmoprep tablets . More

As patents continue to integrate more with core business processes, business intelligence is a key component to ensure maximum efficiency. Most IP systems today focus on inventory and keyword searching; they fail to take advantage of large cost savings and result in missed revenue generation opportunities. By leveraging business intelligence applications, companies can save up to 30‐40% of their total costs through effectively applying quantifiable, repeatable metrics to their day‐to‐day IP operations. Approximately only 42% of all patent applications will be granted by the U.S. Patent and Trademark Office. This means the filing fees for 58% of a company’s patents will be wasted every year because of poor due diligence. With the average patent application costing $20,000, companies filing 50 applications will lose more than $500,000 each year. While this is partially related to prior art availability, there is a much larger problem pertaining to quality assurance and reinforcement of a...

By: iStockAnalyst Tuesday, July 01, 2008 4:29 AM LONDON -(Dow Jones)- Oxford BioMedica (LSE:OXB) , a gene therapy company, Tuesday announced that it has been informed that Bavarian Nordic filed a patent infringement action against Oxford BioMedica (LSE:OXB) , BioMedica Inc. and Oxford BioMedica (LSE:OXB) (U.K.) in the United States District Court for the Southern District of California. These patents correspond to Bavarian Nordic's European Patent No. 1335987, which is the subject of multiple oppositions, all asserting the invalidity of the claimed technology. Bavarian Nordic's claim is that the MVA vector system employed in Oxford BioMedica's (LSE:OXB) therapeutic cancer vaccine, TroVax, which is in clinical development, infringes these U.S. patents. Full article

July 02, 2008: 01:08 PM EST SAN JOSE, Calif., July 2 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, announced today that it has asserted patent infringement claims in the United States District Court, Northern District of California, against biolitec Inc. (Biolitec), Dornier MedTech America, Inc. (Dornier) and NewStar Lasers, Inc. d/b/a CoolTouch, Inc. (CoolTouch). Biolitec, CoolTouch and Dornier market endovenous laser ablation products for use in procedures which VNUS believes infringe several of its patents. VNUS is seeking an injunction prohibiting these companies from selling these products, in addition to monetary damages. The new lawsuit involves patents that VNUS previously asserted in 2005 against Diomed Holdings, Inc., AngioDynamics, Inc. and Vascular Solutions, Inc. VNUS entered into an agreement on June 3, 2008 with AngioDynamics and Vascular So...

AstraZeneca announced on 1st July 2008, that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). Read full article

Important changes after as per US Patent reforms Act ( HR 1908 ) arew as follows: 1. The major reforms will be the change from a first-to-invent to a first-to-file system (harmonising US patent law with the rest of the world), as well as mechanisms for more efficient validity challenges and post-grant review. 2. The reforms are seen as part of a general response in US patent law (and in the US Supreme Court) to concerns regarding the expansion of patents and a subsequent decline in patent quality.

Dialog Open access provides searching of US Patent - Litigations, through LitAlert® from Derwent Information. Data on patent infringement lawsuits filed in the 94 U.S. District Courts and reported to the Commissioner of the U.S. Patents & Trademark Office. 1970 to present. You can search by: * Main Subject * Company * Inventor * Patent Number * Court State * Patent or Litigation Filing Year Operators: You can use AND, OR, NOT and Parentheses to group words together. You can use ? as truncation mark. Sample Document for Search: U.S. Patents - Litigation